Background: Sarcopenia is a common occurrence in people receiving hemodialysis. For hemodialysis patients, early sarcopenia identification is essential since it can be treated with nutritional strategies and exercise. Measurement of muscle mass and strength requires specialised equipment and takes time. Biomarkers are required to assist sarcopenia screening and follow-up. Serum creatinine (SCr), which is impacted by residual renal function and the type of dialysis being used, has been found to be the best biomarker too far for measuring muscle function in hemodialysis patients. In the general population, new biomarkers relating to muscle function have appeared. The aim of the current study is to evaluate the ability of insulin-like growth factor 1(IGF-1) and myostatin to assess muscle status in hemodialysis patients. Patients and Methods: A case control study was conducted on 30 apparently healthy individuals as a control group (Group A)and 30 Egyptian patients on hemodialysis (HD) with muscle wasting Group (B) recruited from Ain Shams University Hospital. Results: On comparing the studied groups, there were significant differences in the characteristics and parameters between the HD patients and healthy control subjects reflect the sarcopenia and malnutrition status in our HD patients. IGF-1 levels were found to be negatively correlated with sarcopenia status in HD patients according to correlation analyses (p 0.05). On the other hand, in HD patients, myostatin levels were p/ositively correlated with the presence of sarcopenia (all p 0.05). Conclusion: Our findings showed that in individuals undergoing HD, IGF-1 and myostatin levels linked with the presence of sarcopenia. To verify these findings, however, additional research is required.